KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abbott Laboratories (ABT) Income towards Parent Company (2016 - 2025)

Abbott Laboratories' Income towards Parent Company history spans 17 years, with the latest figure at $1.8 billion for Q4 2025.

  • For Q4 2025, Income towards Parent Company fell 80.76% year-over-year to $1.8 billion; the TTM value through Dec 2025 reached $6.5 billion, down 51.32%, while the annual FY2025 figure was $6.5 billion, 51.32% down from the prior year.
  • Income towards Parent Company for Q4 2025 was $1.8 billion at Abbott Laboratories, up from $1.6 billion in the prior quarter.
  • Across five years, Income towards Parent Company topped out at $9.2 billion in Q4 2024 and bottomed at $1.0 billion in Q4 2022.
  • The 5-year median for Income towards Parent Company is $1.6 billion (2023), against an average of $2.0 billion.
  • The largest annual shift saw Income towards Parent Company surged 49625.0% in 2021 before it tumbled 80.76% in 2025.
  • A 5-year view of Income towards Parent Company shows it stood at $2.0 billion in 2021, then tumbled by 48.06% to $1.0 billion in 2022, then surged by 54.31% to $1.6 billion in 2023, then soared by 478.98% to $9.2 billion in 2024, then crashed by 80.76% to $1.8 billion in 2025.
  • Per Business Quant, the three most recent readings for ABT's Income towards Parent Company are $1.8 billion (Q4 2025), $1.6 billion (Q3 2025), and $1.8 billion (Q2 2025).